肝型脂肪酸结合蛋白与相关疾病的研究(5)
[30]Plesiński K，Adamczyk P，Swietochowska E，et al.Evaluation of liver-type fatty acid binding protein(L-FABP)and interleukin 6 in children with renal cysts[J].Adv Clin Exp Med，2019，28(12)：1675-1682.
[31]Panduru NM，Forsblom C，Saraheimo M，et al.Urinary liver-type fatty acid binding protein is an independent predictor of stroke and mortality in individuals with type 1 diabetes[J].Diabetologia，2017，60(9)：1782-1790.
[32]Suh JS，Kim SH，Cho KS，et al.Urinary markers in the early stage of nephropathy in patients with childhood-onset type 1 diabetes[J].Pediatr Nephrol，2016，31(4)：623-631.
[33]Yang X，Zhang B，Lu X，et al.Effects of Tangshen Formula on urinary and plasma liver-type fatty acid binding protein levels in patients with type 2 diabetic kidney disease：post-hoc findings from a multi-center，randomized，double-blind，placebo-controlled trial investigating the efficacy and safety of Tangshen Formula in patients with type 2 diabetic kidney disease[J].BMC Complementary and Alternative Medicine，2016(16)：246.
收稿日期：2019-12-26;修回日期：2020-02-01
編辑/杜帆, 百拇医药(王可欣 马心迪 刘剑)
[31]Panduru NM，Forsblom C，Saraheimo M，et al.Urinary liver-type fatty acid binding protein is an independent predictor of stroke and mortality in individuals with type 1 diabetes[J].Diabetologia，2017，60(9)：1782-1790.
[32]Suh JS，Kim SH，Cho KS，et al.Urinary markers in the early stage of nephropathy in patients with childhood-onset type 1 diabetes[J].Pediatr Nephrol，2016，31(4)：623-631.
[33]Yang X，Zhang B，Lu X，et al.Effects of Tangshen Formula on urinary and plasma liver-type fatty acid binding protein levels in patients with type 2 diabetic kidney disease：post-hoc findings from a multi-center，randomized，double-blind，placebo-controlled trial investigating the efficacy and safety of Tangshen Formula in patients with type 2 diabetic kidney disease[J].BMC Complementary and Alternative Medicine，2016(16)：246.
收稿日期：2019-12-26;修回日期：2020-02-01
編辑/杜帆, 百拇医药(王可欣 马心迪 刘剑)